Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) EBITDA (2018 - 2025)

Entera Bio has reported EBITDA over the past 8 years, most recently at -$3.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 29.61% year-over-year to -$3.0 million, compared with a TTM value of -$11.5 million through Dec 2025, down 20.15%, and an annual FY2025 reading of -$11.5 million, down 20.28% over the prior year.
  • EBITDA came in at -$3.0 million for Q4 2025, up from -$3.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $9.5 million in Q1 2021 to a low of -$4.1 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$2.5 million (2023), compared with a mean of -$1.5 million.
  • The sharpest move saw EBITDA surged 225.15% in 2021, then crashed 216.42% in 2022.
  • Over 5 years, EBITDA stood at -$4.1 million in 2021, then rose by 24.95% to -$3.1 million in 2022, then surged by 36.02% to -$2.0 million in 2023, then dropped by 19.05% to -$2.3 million in 2024, then fell by 29.61% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's EBITDA are -$3.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$2.7 million (Q2 2025).